The federal 340B Drug Pricing Program lowers outpatient drug prices for specific categories of "covered entity" hospitals and clinics. Covered entities can access 340B drug pricing for all of their eligible patients, including those with insurance. The program has always generated some level of controversy, but more in recent times. Drug manufacturers and safety net providers are using a wide array of tools and outlets — including interest groups, lobbying, and media — to share their divergent perspectives on the purpose and appropriate role of 340B. While interest groups are becoming more vocal, the federal government is simultaneously implementing changes in program administration and oversight in response to internal and external calls for transparency and accountability. This Perspective presents the history, current status, and future trajectory of the 340B program.
The research described in this report was performed under the auspices of RAND Health.
This publication is part of the RAND Corporation Perspective series. RAND Perspectives present expert insights on timely policy issues. All RAND Perspectives undergo peer review to ensure high standards for quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.